ClinicalTrials.Veeva

Menu

CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea (COCTAEyl)

C

Centre Hospitalier Intercommunal Creteil

Status

Active, not recruiting

Conditions

Exudative Macular Degeneration
AMD

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT03803631
COCTAEyl

Details and patient eligibility

About

The main objective of this study is to analyze a new noninvasive imaging examination, OCT angiography, in the evaluation of neovascular remodeling and early signs of recurrence of wet AMD undergoing treatment on OCTA and to correlate OCTA findings with SD-OCT findings.

Enrollment

49 patients

Sex

All

Ages

55+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Naïve patients
  • Type 1 or type 2 Choroidal NeoVascularization (CNV)
  • Age ≥ 55 years
  • Presence of subfoveal CNV secondary to Age-related Macular Degeneration (AMD)
  • At the time of inclusion, multimodal imaging should reveal exudative features
  • Exudative AMD diagnosis established between 1 and 7 days before inclusion
  • Monitored monthly
  • Loading phase then bimonthly retreatment.
  • Signed Informed Consent.
  • Patient covered by the French Health Insurance

Exclusion criteria

  • Polypoidal choroidal vasculopathy
  • Type 3 neovascularization
  • Choroidal neovascularization attributable to causes other than AMD
  • Macular hematoma
  • Pigment epithelial detachment higher than 150µm
  • Fibrosis > 50% lesion on fundus color photography, fibroglial scar
  • Media opacity annoying acquisition
  • Retinal vascular occlusion
  • Diabetic retinopathy
  • Adult-onset foveomacular vitelliform dystrophy and other pattern dystrophies,
  • Refractive error >-6D
  • Active intraocular inflammation in the study eye
  • Patient who does not meet the local indication criteria for Eylea® treatment. Contraindications listed in the SmPCs must be taken into account
  • Patient taking part in an interventional study at the time of enrolment.
  • Any history of allergy to the antiseptic used during preparation of the eye for the IVT injection in the investigational site (e.g. povidone iodine or chlorhexidine).
  • Pregnant and lactating women
  • Stroke and/or myocardial infarction 3 months before inclusion

Trial contacts and locations

5

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems